Market News / Story
Perspective Granted FDA Fast Track for PSV359 in FAP-Positive Solitary Fibrous Tumors
·
Perspective announced FDA Fast Track designation for PSV359 to treat adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. Key Highlights: FDA granted Fast Track Designation for PSV359 in FAP-positive solitary fibrous tumors to expedite development and review. PSV359 is an investigational FAP-targeted alpha therapy being evaluated in an ongoing Phase 1/2a study for advanced FAP-positive solid tumors. Early human…